Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 5/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.36 |
| ▸ | CDK2 | P24941 | 7/20 | 0.36 |
| ▸ | CDK9 | P50750 | 6/20 | 0.36 |
| ▸ | CCNK | O75909 | 5/20 | 0.36 |
| ▸ | CCND3 | P30281 | 5/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661346 | 1.00 | INSR (0.39) | INSRALKCCNA2CDK2CDK9 | |
| SCHEMBL29661395 | 0.93 | MAP4K1 (0.38) | INSRALKCCNA2CDK2CDK9 | |
| SCHEMBL24327605 | 0.93 | MAP4K1 (0.38) | INSRALKCCNA2CDK2CDK9 | |
| SCHEMBL24327586 | 0.81 | IGF1R (0.35) | CCNA2CDK2CDK9CCNKCCND3 | |
| SCHEMBL26778562 | 0.80 | NISCH (0.44) | CCNA2CDK2CDK9CCNKCCND3 | |
| SCHEMBL379494 | 0.77 | SRC (0.47) | SRCAKT1 | |
| SCHEMBL4100395 | 0.76 | CCNA2 (0.35) | INSRALKCCNA2CDK2CDK9 | |
| SCHEMBL24326962 | 0.75 | ULK1 (0.35) | ALKCCNA2CDK2CDK9CCNK | |
| SCHEMBL29661362 | 0.75 | ULK1 (0.35) | ALKCCNA2CDK2CDK9CCNK | |
| SCHEMBL4099937 | 0.74 | CXCR2 (0.44) | ALKCCNA2CDK2CDK9CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | INSR 82/4885ALK 13/4885CCNA2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.